A Phase 3 trial in Barcelona, Spain, showed that the immunotherapy drug retifanlimab in combination with chemotherapy helped slow down disease progression in patients with anal squamous cell carcinoma, a cancer often caused by human papillomavirus. The study found that adding retifanlimab to chemotherapy reduced the risk of disease progression or death by more than a third, with patients on the combination treatment going 9.3 months without disease progression compared to 7.4 months for those on chemotherapy alone. While the combination also showed higher rates of overall survival, additional long-term data is needed to confirm this advantage.
Source link
Incyte’s checkpoint inhibitor delays disease progression in anal cancer trial
